Toronto, Ontario–(Newsfile Corp. – March 17, 2025) – Neural Therapeutics Inc. (CSE: NURL) (“Neural” or the “Company”), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs
NEW YORK–(BUSINESS WIRE)– Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain
VANCOUVER, BC, March 17, 2025 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, today announced
Toronto, Ontario–(Newsfile Corp. – March 14, 2025) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“), a life sciences company
Raanana, Israel, March 14, 2025 (GLOBE NEWSWIRE) — Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels,
Vancouver, British Columbia–(Newsfile Corp. – March 12, 2025) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a GMP-compliant, Health
NEW YORK and BERLIN, March 11, 2025 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment
TORONTO, March 10, 2025 (GLOBE NEWSWIRE) — Psyence Group Inc (“Psyence Group” or the “Company“) (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical
BOSTON, MA, March 07, 2025 (GLOBE NEWSWIRE) — Netcapital Inc. (NASDAQ: NCPL, NCPLW), a digital private capital markets ecosystem, today announced that its subsidiary, Netcapital Securities Inc.
NEW YORK–(BUSINESS WIRE)– Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain